Iovance draws focus after real-world Amtagvi data and post-approval sales growth
Iovance reported real-world data suggesting Amtagvi may have a best in class profile in advanced melanoma. The company posted $263.5 million in annual sales after 2024 approval, while pursuing broader use and facing regulatory and logistics risks.
Iovance Biotherapeutics recently reported real world data suggesting its commercial TIL therapy Amtagvi may have a best in class profile with strong response rates in advanced melanoma, which has refocused attention on the stock. The data arrives after the company secured approval for the advanced melanoma treatment in 2024. Sales for the company, primarily from this new therapy, reached $263.5 million last year, representing an increase of nearly 61% from the prior fiscal year.
Amtagvi is the first therapy of its category approved for this form of melanoma and its availability is gradually expanding internationally. It received approval in Canada last year and may gain regulatory clearance in several European nations and Australia in the coming years. Based on its current commercial trajectory, some projections suggest Amtagvi could achieve annual sales surpassing $1 billion by 2030.
The company is also seeking to broaden the approved uses for its therapy, known generically as lifileucel. Recent early results from a key clinical trial in patients with advanced soft-tissue sarcomas were positive. The company estimates an annual patient population exceeding 8,000 for this potential new indication in the U.S. and Europe.
The real world Amtagvi data arrives after a volatile few years for shareholders. The recent 30 day share price return of 15.77% and a 1 day move of 1.98% at a US$2.57 share price stand in contrast to a 1 year total shareholder return decline of 53.86% and a 5 year total shareholder return decline of 94.55%.
Despite the promising start for its lead product, Iovance Biotherapeutics faces risks common to small drug developers. Clinical or regulatory setbacks could cause a sharp decline in the company's stock value. These treatments are complex to administer, requiring a multi-step process where cells are harvested from a patient, manufactured over approximately 34 days, and then reinfused following chemotherapy. This procedure is typically conducted only at specialized, authorized treatment centers.
With the shares at US$2.57, a value score of 4, an intrinsic discount of 90.72% and a market price sitting well below analyst targets, the company also faces risks that upside could be knocked off course if EMA approval setbacks drag on or if heavy dependence on high priced Amtagvi leads to payer pushback.